| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $152,183 | 2 | 7 |
Sells | $10,135,446 | 26 | 93 |
| Firestone Karen | director | 2 | $152,183 | 0 | $0 | $152,183 |
| Bedrosian Camille L | Chief Medical Officer | 0 | $0 | 3 | $513,492 | $-513,492 |
| FRATES JAMES M | Chief Financial Officer | 0 | $0 | 4 | $553,723 | $-553,723 |
| MILNE GEORGE M JR | director | 0 | $0 | 1 | $830,904 | $-830,904 |
| Mazzariello Gina | Chief Legal Officer | 0 | $0 | 6 | $1.05M | $-1.05M |
| Klee Justin B. | Co-Chief Executive Officer | 0 | $0 | 6 | $3.59M | $-3.59M |
| Cohen Joshua B | Co-Chief Executive Officer | 0 | $0 | 6 | $3.6M | $-3.6M |
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is …
Over the last 12 months, insiders at Amylyx Pharmaceuticals, Inc. have bought $152,183 and sold $10.14M worth of Amylyx Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Amylyx Pharmaceuticals, Inc. have bought $10.05M and sold $9.96M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Firestone Karen (director) — $152,183.
The last purchase of 3,800 shares for transaction amount of $51,338 was made by Firestone Karen (director) on 2026‑05‑21.
| 2026-10-05 | Sale | MILNE GEORGE M JR | director | 30,000 0.0269% | $27.70 | $830,904 | +0.94% | |
| 2026-09-10 | Sale | Cohen Joshua B | Co-Chief Executive Officer | 30,464 0.0275% | $32.19 | $980,504 | -10.80% | |
| 2026-09-10 | Sale | Klee Justin B. | Co-Chief Executive Officer | 30,464 0.0275% | $32.18 | $980,263 | -10.80% | |
| 2026-09-10 | Sale | Bedrosian Camille L | Chief Medical Officer | 10,028 0.0091% | $32.40 | $324,868 | -10.80% | |
| 2026-09-10 | Sale | FRATES JAMES M | Chief Financial Officer | 10,810 0.0098% | $32.36 | $349,821 | -10.80% | |
| 2026-09-10 | Sale | Mazzariello Gina | Chief Legal Officer | 9,536 0.0087% | $32.46 | $309,506 | -10.80% | |
| 2026-07-10 | Sale | Mazzariello Gina | Chief Legal Officer | 15,000 0.0179% | $17.61 | $264,122 | +57.96% | |
| 2026-07-09 | Sale | Mazzariello Gina | Chief Legal Officer | 15,000 0.018% | $18.32 | $274,746 | +52.64% | |
| 2026-05-21 | Firestone Karen | director | 3,800 0.0044% | $13.51 | $51,338 | +68.63% | ||
| 2026-03-02 | Sale | Cohen Joshua B | Co-Chief Executive Officer | 29,282 0.0336% | $14.48 | $424,120 | +16.14% | |
| 2026-03-02 | Sale | Klee Justin B. | Co-Chief Executive Officer | 29,282 0.0336% | $14.47 | $423,760 | +16.14% | |
| 2026-03-02 | Sale | Bedrosian Camille L | Chief Medical Officer | 6,461 0.0075% | $14.58 | $94,205 | +16.14% | |
| 2026-03-02 | Sale | FRATES JAMES M | Chief Financial Officer | 7,909 0.0091% | $14.52 | $114,851 | +16.14% | |
| 2026-03-02 | Sale | Mazzariello Gina | Chief Legal Officer | 6,844 0.0079% | $14.52 | $99,378 | +16.14% | |
| 2026-02-23 | Sale | Mazzariello Gina | Chief Legal Officer | 3,419 0.0042% | $14.14 | $48,352 | +27.45% | |
| 2026-02-02 | Sale | Cohen Joshua B | Co-Chief Executive Officer | 15,500 0.0187% | $14.68 | $227,593 | +18.78% | |
| 2026-02-02 | Sale | Klee Justin B. | Co-Chief Executive Officer | 15,500 0.0187% | $14.69 | $227,618 | +18.78% | |
| 2026-02-02 | Sale | FRATES JAMES M | Chief Financial Officer | 3,557 0.0043% | $14.65 | $52,097 | +18.78% | |
| 2026-02-02 | Sale | Mazzariello Gina | Chief Legal Officer | 3,448 0.0041% | $14.65 | $50,516 | +18.78% | |
| 2026-01-16 | Sale | Cohen Joshua B | Co-Chief Executive Officer | 1,974 0.0023% | $13.83 | $27,299 | +19.09% |
| MILNE GEORGE M JR | director | 782881 0.6237% | $22.86M | 2 | 2 | +73.62% |
| FRATES JAMES M | Chief Financial Officer | 233625 0.1861% | $6.82M | 1 | 11 | +91.57% |
| Firestone Karen | director | 66900 0.0533% | $1.95M | 5 | 0 | +109.32% |
| Morningside Venture Investments Ltd | 10 percent owner | 6997302 5.575% | $204.32M | 1 | 10 | +23.76% |
| VIKING GLOBAL INVESTORS LP | 2300000 1.8325% | $67.16M | 1 | 0 | +23.76% | |
| Olinger Margaret | Chief Commercial Officer | 214355 0.1708% | $6.26M | 1 | 1 | +36.36% |
| Zeiher Bernhardt G | director | 10000 0.008% | $292,000.00 | 1 | 0 | +217.69% |
| Cheng Isaac | director | 6578 0.0052% | $192,077.60 | 1 | 0 | +36.36% |
| Quimi Daphne | director | 5000 0.004% | $146,000.00 | 2 | 0 | +89.06% |
| FONTEYNE PAUL R. | director | 3947 0.0031% | $115,252.40 | 1 | 0 | +36.36% |
$104,428,685 | 44 | 22.55% | $3.78B | |
$1,275,975,557 | 32 | 19.44% | $3.54B | |
$151,136,640 | 31 | -1.41% | $3.95B | |
$5,066,938 | 27 | 26.38% | $3.7B | |
$169,745,779 | 25 | 31.94% | $4B |
| Increased Positions | 110 | +62.5% | 21M | +19.37% |
| Decreased Positions | 76 | -43.18% | 19M | -17.28% |
| New Positions | 41 | New | 4M | New |
| Sold Out Positions | 30 | Sold Out | 5M | Sold Out |
| Total Postitions | 210 | +19.32% | 112M | +2.1% |
| Fmr Llc | $129,951.00 | 10.35% | 11.38M | +8M | +273.33% | 2025-09-30 |
| Perceptive Advisors Llc | $102,236.00 | 8.14% | 8.95M | +1M | +13.29% | 2025-09-30 |
| Blackrock, Inc. | $81,547.00 | 6.49% | 7.14M | +2M | +29.59% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $77,848.00 | 6.2% | 6.82M | -2M | -22.54% | 2025-09-30 |
| Tcg Crossover Management, Llc | $71,304.00 | 5.68% | 6.24M | +300,000 | +5.05% | 2025-09-30 |
| Vanguard Group Inc | $60,226.00 | 4.79% | 5.27M | +775,722 | +17.25% | 2025-09-30 |
| Saturn V Capital Management Lp | $52,588.00 | 4.19% | 4.6M | +1M | +41.23% | 2025-09-30 |
| Commodore Capital Lp | $46,542.00 | 3.71% | 4.08M | +4M | New | 2025-09-30 |
| First Light Asset Management, Llc | $38,324.00 | 3.05% | 3.36M | +3M | New | 2025-09-30 |
| Point72 Asset Management, L.P. | $31,863.00 | 2.54% | 2.79M | -2M | -38.49% | 2025-09-30 |